Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 4/2013

01-07-2013 | Original Article

An update on serine deficiency disorders

Authors: S. N. van der Crabben, N. M. Verhoeven-Duif, E. H. Brilstra, L. Van Maldergem, T. Coskun, E. Rubio-Gozalbo, R. Berger, T. J. de Koning

Published in: Journal of Inherited Metabolic Disease | Issue 4/2013

Login to get access

Abstract

Serine deficiency disorders are caused by a defect in one of the three synthesising enzymes of the L-serine biosynthesis pathway. Serine deficiency disorders give rise to a neurological phenotype with psychomotor retardation, microcephaly and seizures in newborns and children or progressive polyneuropathy in adult patients. There are three defects that cause serine deficiency of which 3-phosphoglycerate dehydrogenase (3-PGDH) deficiency, the defect affecting the first step in the pathway, has been reported most frequently. The other two disorders in L-serine biosynthesis phosphoserine aminotransferase (PSAT) deficiency and phosphoserine phosphatase (PSP) deficiency have been reported only in a limited number of patients. The biochemical hallmarks of all three disorders are low concentrations of serine in cerebrospinal fluid and plasma. Prompt recognition of affected patients is important, since serine deficiency disorders are treatable causes of neurometabolic disorders. The use of age-related reference values for serine in CSF and plasma can be of great help in establishing a correct diagnosis of serine deficiency, in particular in newborns and young children.
Literature
go back to reference De Klerk JB, Huijmans JGM, Catsman-Berrevoets CE, et al Disturbed biosyn- thesis o(1f serine: a second phenotype with axonal polyneuropathy and ichthyosis. Abstracts of the annual meeting of the Erfelijke Stofwisselingsziekten Nederland; October 13, 1996; Masstricht, the Netherlands De Klerk JB, Huijmans JGM, Catsman-Berrevoets CE, et al Disturbed biosyn- thesis o(1f serine: a second phenotype with axonal polyneuropathy and ichthyosis. Abstracts of the annual meeting of the Erfelijke Stofwisselingsziekten Nederland; October 13, 1996; Masstricht, the Netherlands
go back to reference de Koning TJ (2012) Serine synthesis defects and epilepsy (chapter 18) In: Pearl P (ed) Inherited metabolic epilepsies. Demos Medical Publishing, New York. de Koning TJ (2012) Serine synthesis defects and epilepsy (chapter 18) In: Pearl P (ed) Inherited metabolic epilepsies. Demos Medical Publishing, New York.
go back to reference de Koning TJ, Duran M, Dorland L et al (1998) Beneficial effects of L-serine and glycine in the management of seizures in 3-phosphoglycerate dehydrogenase deficiency. Ann Neurol 44(2):261–265PubMedCrossRef de Koning TJ, Duran M, Dorland L et al (1998) Beneficial effects of L-serine and glycine in the management of seizures in 3-phosphoglycerate dehydrogenase deficiency. Ann Neurol 44(2):261–265PubMedCrossRef
go back to reference de Koning TJ, Jaeken J, Pineda M, Van ML, Poll-The BT, van der Knaap MS (2000) Hypomyelination and reversible white matter attenuation in 3-phosphoglycerate dehydrogenase deficiency. Neuropediatrics 31(6):287–292PubMedCrossRef de Koning TJ, Jaeken J, Pineda M, Van ML, Poll-The BT, van der Knaap MS (2000) Hypomyelination and reversible white matter attenuation in 3-phosphoglycerate dehydrogenase deficiency. Neuropediatrics 31(6):287–292PubMedCrossRef
go back to reference de Koning TJ, Duran M, Van ML et al (2002) Congenital microcephaly and seizures due to 3-phosphoglycerate dehydrogenase deficiency: outcome of treatment with amino acids. J Inherit Metab Dis 25(2):119–125PubMedCrossRef de Koning TJ, Duran M, Van ML et al (2002) Congenital microcephaly and seizures due to 3-phosphoglycerate dehydrogenase deficiency: outcome of treatment with amino acids. J Inherit Metab Dis 25(2):119–125PubMedCrossRef
go back to reference de Koning TJ, Klomp LW, van Oppen AC et al (2004) Prenatal and early postnatal treatment in 3-phosphoglycerate-dehydrogenase deficiency. Lancet 364:2221–2222PubMedCrossRef de Koning TJ, Klomp LW, van Oppen AC et al (2004) Prenatal and early postnatal treatment in 3-phosphoglycerate-dehydrogenase deficiency. Lancet 364:2221–2222PubMedCrossRef
go back to reference Hart CE, Race V, Achouri Y et al (2007) Phosphoserine aminotransferase deficiency: a novel disorder of the serine biosynthesis pathway. Am J Hum Genet 80:931–937PubMedCrossRef Hart CE, Race V, Achouri Y et al (2007) Phosphoserine aminotransferase deficiency: a novel disorder of the serine biosynthesis pathway. Am J Hum Genet 80:931–937PubMedCrossRef
go back to reference Hausler MG, Jaeken J, Monch E, Ramaekers VT (2001) Phenotypic heterogeneity and adverse effects of serine treatment in 3-phosphoglycerate dehydrogenase deficiency: report on two siblings. Neuropediatrics 32(4):191–195PubMedCrossRef Hausler MG, Jaeken J, Monch E, Ramaekers VT (2001) Phenotypic heterogeneity and adverse effects of serine treatment in 3-phosphoglycerate dehydrogenase deficiency: report on two siblings. Neuropediatrics 32(4):191–195PubMedCrossRef
go back to reference Jaeken J, Detheux M, Van Maldergem L, Frijns JP, Alliet P, Foulon M, Carchon H, Van Schaftingen E (1996a) 3-Phosphoglycerate dehydrogenase deficiency and 3-phosphoserine phosphatase deficiency: inborn errors of serine biosynthesis. J Inherit Metab Dis 19:223–226PubMedCrossRef Jaeken J, Detheux M, Van Maldergem L, Frijns JP, Alliet P, Foulon M, Carchon H, Van Schaftingen E (1996a) 3-Phosphoglycerate dehydrogenase deficiency and 3-phosphoserine phosphatase deficiency: inborn errors of serine biosynthesis. J Inherit Metab Dis 19:223–226PubMedCrossRef
go back to reference Jaeken J, Detheux M, Van ML, Foulon M, Carchon H, Van SE (1996b) 3-Phosphoglycerate dehydrogenase deficiency: an inborn error of serine biosynthesis. Arch Dis Child 74(6):542–545PubMedCrossRef Jaeken J, Detheux M, Van ML, Foulon M, Carchon H, Van SE (1996b) 3-Phosphoglycerate dehydrogenase deficiency: an inborn error of serine biosynthesis. Arch Dis Child 74(6):542–545PubMedCrossRef
go back to reference Jaeken J, Detheux M, Fryns JP et al (1997) Phosphoserine phosphatase deficiency in a patient with Williams syndrome. J Med Genet 34:594–596PubMedCrossRef Jaeken J, Detheux M, Fryns JP et al (1997) Phosphoserine phosphatase deficiency in a patient with Williams syndrome. J Med Genet 34:594–596PubMedCrossRef
go back to reference Keularts IM, Leroy PL, Rubio-Gozalbo EM, Spaapen LJ, Weber B, Dorland B, de Koning TJ, Verhoeven-Duif NM (2010) Fatal cerebral edema associated with serine deficiency in CSF. J Inherit Metab Dis doi:10.1007/s10545-010-9067-9 Keularts IM, Leroy PL, Rubio-Gozalbo EM, Spaapen LJ, Weber B, Dorland B, de Koning TJ, Verhoeven-Duif NM (2010) Fatal cerebral edema associated with serine deficiency in CSF. J Inherit Metab Dis doi:10.​1007/​s10545-010-9067-9
go back to reference Méneret A, Wiame E, Marelli C, Lenglet T, Van Schaftingen E, Sedel F (2012) A serine synthesis defect presenting with a charcot-marie-tooth-like polyneuropathy. Arch Neurol 69(7):908-11 Méneret A, Wiame E, Marelli C, Lenglet T, Van Schaftingen E, Sedel F (2012) A serine synthesis defect presenting with a charcot-marie-tooth-like polyneuropathy. Arch Neurol 69(7):908-11
go back to reference Moat SJ, Carling R, Nix B, Henderson M, Briddon A, Prunty H, Talbot R, Powell A, Wright K, Fuchs SA, de Koning TJ (2010) Multicentre age related reference intervals for cerebrospinal fluid serine: Implications for the diagnosis and follow-up of serine biosynthesis disorders. Mol Genet Metab 101:149–152PubMedCrossRef Moat SJ, Carling R, Nix B, Henderson M, Briddon A, Prunty H, Talbot R, Powell A, Wright K, Fuchs SA, de Koning TJ (2010) Multicentre age related reference intervals for cerebrospinal fluid serine: Implications for the diagnosis and follow-up of serine biosynthesis disorders. Mol Genet Metab 101:149–152PubMedCrossRef
go back to reference Pind S, Slominski E, Mauthe J et al (2002) V490M, a common mutation in 3-phosphoglycerate dehydrogenase deficiency, causes enzyme deficiency by decreasing the yield of mature enzyme. J Biol Chem 277(9):7136–7143PubMedCrossRef Pind S, Slominski E, Mauthe J et al (2002) V490M, a common mutation in 3-phosphoglycerate dehydrogenase deficiency, causes enzyme deficiency by decreasing the yield of mature enzyme. J Biol Chem 277(9):7136–7143PubMedCrossRef
go back to reference Pineda M, Vilaseca MA, Artuch R et al (2000) 3-phosphoglycerate dehydrogenase deficiency in a patient with West syndrome. Dev Med Child Neurol 42(9):629–633PubMedCrossRef Pineda M, Vilaseca MA, Artuch R et al (2000) 3-phosphoglycerate dehydrogenase deficiency in a patient with West syndrome. Dev Med Child Neurol 42(9):629–633PubMedCrossRef
go back to reference Surtees R, Bowron A, Leonard J (1997) Cerebrospinal fluid and plasma total homocysteine and related metabolites in children with cystathionine beta-synthase deficiency: the effect of treatment. Pediatr Res 42:577–582PubMedCrossRef Surtees R, Bowron A, Leonard J (1997) Cerebrospinal fluid and plasma total homocysteine and related metabolites in children with cystathionine beta-synthase deficiency: the effect of treatment. Pediatr Res 42:577–582PubMedCrossRef
go back to reference Tabatabaie L, de Koning TJ, Geboers AJ (2009) van dB, I, Berger R, Klomp LW. Novel mutations in 3-phosphoglycerate dehydrogenase (PHGDH) are distributed throughout the protein and result in altered enzyme kinetics. Hum Mutat 30(5):749–756PubMedCrossRef Tabatabaie L, de Koning TJ, Geboers AJ (2009) van dB, I, Berger R, Klomp LW. Novel mutations in 3-phosphoglycerate dehydrogenase (PHGDH) are distributed throughout the protein and result in altered enzyme kinetics. Hum Mutat 30(5):749–756PubMedCrossRef
go back to reference Tabatabaie L, Klomp LWJ, Rubio-Gozalbo ME, Spaapen LJM, Haagen AAM, Dorland L, de Koning TJ (2011) Expanding the Clinical Spectrum of 3-Phosphoglycerate Dehydrogenase Deficiency. J Inherit Metab Dis 34(1):181–184PubMedCrossRef Tabatabaie L, Klomp LWJ, Rubio-Gozalbo ME, Spaapen LJM, Haagen AAM, Dorland L, de Koning TJ (2011) Expanding the Clinical Spectrum of 3-Phosphoglycerate Dehydrogenase Deficiency. J Inherit Metab Dis 34(1):181–184PubMedCrossRef
go back to reference Veiga-da-Cunha M, Collet JF, Prieur B et al (2004) Mutations responsible for 3-phosphoserine phosphatase deficiency. Eur J Hum Genet 12:163–166PubMedCrossRef Veiga-da-Cunha M, Collet JF, Prieur B et al (2004) Mutations responsible for 3-phosphoserine phosphatase deficiency. Eur J Hum Genet 12:163–166PubMedCrossRef
go back to reference Visser WF, Verhoeven-Duif NM, Ophoff R, Bakker S, Klomp LW, Berger R, de Koning TJ (2011) A sensitive and simple ultra-high-performance-liquid chromatography-tandem mass spectrometry based method for the quantification of D-amino acids in body fluids. J Chromatogr A 1218:7130–7136PubMedCrossRef Visser WF, Verhoeven-Duif NM, Ophoff R, Bakker S, Klomp LW, Berger R, de Koning TJ (2011) A sensitive and simple ultra-high-performance-liquid chromatography-tandem mass spectrometry based method for the quantification of D-amino acids in body fluids. J Chromatogr A 1218:7130–7136PubMedCrossRef
Metadata
Title
An update on serine deficiency disorders
Authors
S. N. van der Crabben
N. M. Verhoeven-Duif
E. H. Brilstra
L. Van Maldergem
T. Coskun
E. Rubio-Gozalbo
R. Berger
T. J. de Koning
Publication date
01-07-2013
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 4/2013
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-013-9592-4

Other articles of this Issue 4/2013

Journal of Inherited Metabolic Disease 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.